S

Sanofi

Global pharma company; vaccines and R&D

Quality Lead New Grad

Full-TimeUpdated on 10/14/2026Deadline 11/30/26
No salary listed
Entry
Master's, MBA
Beijing, China
In Person
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • A Master's degree in Pharmaceutical Sciences, Biotechnology, Chemical Engineering, Life Sciences, or a related technical discipline is required; a top MBA with relevant manufacturing exposure is also considered.
  • At least 2–3 years of experience in pharmaceutical quality assurance, quality control, manufacturing, or related regulatory/compliance roles, ideally in GMP-regulated environments.
  • Demonstrated exposure to cGMP operations, quality-event investigations (deviations, out-of-specification events, and corrective/preventive actions), and regulatory compliance.
  • Fluency in English is required.
  • In-depth knowledge of the biologic product license application process and associated regulatory requirements.
  • Know-how in quality systems, quality risk management, continuous improvement management, GxP, health-regulated regulations, and international and FDA exposure.
Responsibilities
  • Perform routine and non-routine analytical testing of raw materials, in-process samples, finished products, and stability samples in compliance with standard operating procedures, GxP, and regulatory requirements.
  • Support QC laboratory equipment qualification, calibration, and preventive maintenance activities.
  • Assist in analytical method verification and validation activities under supervision.
  • Document test results accurately and in a timely manner in compliance with data integrity standards.
  • Participate in deviation investigations, root cause analysis, and corrective/preventive action follow-up.
  • Contribute to laboratory housekeeping, safety compliance, and 5S/continuous improvement initiatives.
  • Support QC data trend analysis and escalate anomalies to senior managers.
  • Support inspection readiness for national and international regulatory agencies, including NMPA, FDA, and EMEA, and learn to implement agency-specific requirements.
  • Participate in self-audits, global audits, and regulatory inspections, building knowledge of compliance expectations and audit response strategies.
  • Contribute to a contamination control strategy and sterility assurance system for sterile and non-sterile products.
  • Collaborate with Production, Quality Assurance, and Regulatory Affairs teams.
  • Partner with Production, Quality Assurance, Engineering, and Supply Chain teams to align quality control operations across manufacturing operations.
  • Provide QC support during product launches, technical studies, and validation activities, practicing influence without direct authority.
  • Support training and development of QC team members and promote quality culture, GMP awareness, and continuous learning.
  • Progressively take on people-management responsibilities, including performance evaluation and individual development planning by Year 3.
  • Engage in the Early Talent Program's learning curriculum, mentoring sessions, and rotational assessments.
Desired Qualifications
  • Experience or strong interest in sterile manufacturing, contamination control, or biologics quality systems.
  • Familiarity with Chinese cGMP (NMPA), FDA, and/or EMEA regulatory frameworks.
  • KNEAT solution experience is a plus.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Professional Development Budget

Parental Leave

Company News

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...

U.S. Securities and Exchange Commission
Sep 20th, 2026
8-K

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)